[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of HP-001 capsules in patients with relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma
评估HP-001胶囊在复发难治的多发性骨髓瘤和非霍奇金淋巴瘤患者中的安全性。
评估最大耐受剂量(MTD)并确定 II 期临床研究推荐剂量(RP2D)。
[Translation] To evaluate the safety of HP-001 capsules in patients with relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma.
To evaluate the maximum tolerated dose (MTD) and determine the recommended dose (RP2D) for Phase II clinical studies.